Lead Product(s) : Delpazolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 22, 2023
Lead Product(s) : Delpazolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Delpazolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 04, 2022
Lead Product(s) : Delpazolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Delpazolid
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial to Evaluate Bioequivalence of LCB01-0371 in Different Batches
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 25, 2021
Lead Product(s) : Delpazolid
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Delpazolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Ludwig Maximilian University of Munich | Radboud University Medical Center | University of California, San Francisco
Deal Size : Inapplicable
Deal Type : Inapplicable
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 16, 2020
Lead Product(s) : Delpazolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Ludwig Maximilian University of Munich | Radboud University Medical Center | University of California, San Francisco
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Delpazolid
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2018
Lead Product(s) : Delpazolid
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Delpazolid
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IV Dosage Form of LCB01-0371 Phase I Study in Healthy Male Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 30, 2016
Lead Product(s) : Delpazolid
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Delpazolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 19, 2016
Lead Product(s) : Delpazolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Delpazolid
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Multiple Ascending Dose, Phase 1 Clinical Study of LCB01-0371
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 04, 2015
Lead Product(s) : Delpazolid
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Delpazolid
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
To Evaluate the Effect of Food on Pharmacokinetics(PK), Phase I Clinical Study of LCB01-0371
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 02, 2015
Lead Product(s) : Delpazolid
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Delpazolid
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
An Open-label, Single Dose, Parallel Design, Phase 1 Clinical Study of LCB01-0371
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 20, 2015
Lead Product(s) : Delpazolid
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable